Sergio Schwartzman is a Rheumatology/Immunology physician affiliated with Hospital for Special Surgery. OpenAlex indexes 122 publications with 4,033 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
535 E 70th St
New York, NY 100214872
Telephone
212-606-1557Registry record last updated 21 Jan 2015.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202590 payments$113,202openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202594 payments$78,558openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year202566 payments$58,421openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.3%Interleukin-17A Antagonist19%Taltz Autoinjector63%Cosentyx Sensoready (2 Pens)37%Part D<11 patientsFolate Analog Metabolic Inhibitor7.1%Methotrexate100%Part D<11 patients+ 5 more classes in this area
Dermatology
16.6%Corticosteroid16.6%Methylprednisolone100%Part D≥17 patientsMetabolism & gastrointestinal
12.6%Corticosteroid12.6%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation
Journal of the American Academy of Dermatology
2024 - Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology
2024 - Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
Journal of the American Academy of Dermatology
2023 - Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation
Journal of the American Academy of Dermatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lockshin, MD
Hospital for Special Surgery
Lionel Ivashkiv, MD
Hospital for Special Surgery
Vivian Bykerk, VIVIAN, BYKERK, MD
Hospital for Special Surgery
Jane Salmon, MD
Hospital for Special Surgery
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”